131 related articles for article (PubMed ID: 38387509)
21. Can we omit systematic biopsies in patients undergoing MRI fusion-targeted prostate biopsies?
Leow JJ; Koh SH; Chow MW; Loke W; Salada R; Hong SK; Yeow Y; Lee CH; Tan CH; Tan TW
Asian J Androl; 2023; 25(1):43-49. PubMed ID: 35488666
[TBL] [Abstract][Full Text] [Related]
22. Comparison of prostate cancer detection rates between magnetic resonance imaging-targeted biopsy and transrectal ultrasound-guided biopsy according to Prostate Imaging Reporting and Data System in patients with PSA ≥4 ng/mL: a systematic review and meta-analysis.
Zhu K; Qin Z; Xue J; Miao C; Tian Y; Liu S; Zhu S; Gu Q; Hou C; Xu A; Yang J; Wang Z
Transl Androl Urol; 2019 Dec; 8(6):741-753. PubMed ID: 32038971
[TBL] [Abstract][Full Text] [Related]
23. A cohort of transperineal electromagnetically tracked magnetic resonance imaging/ultrasonography fusion-guided biopsy: assessing the impact of inter-reader variability on cancer detection.
Wajswol E; Winoker JS; Anastos H; Falagario U; Okhawere K; Martini A; Treacy PJ; Voutsinas N; Knauer CJ; Sfakianos JP; Lewis SC; Taouli BA; Rastinehad AR
BJU Int; 2020 Apr; 125(4):531-540. PubMed ID: 31762182
[TBL] [Abstract][Full Text] [Related]
24. Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different software-based systems.
Hanske J; Risse Y; Roghmann F; Pucheril D; Berg S; Tully KH; von Landenberg N; Wald J; Noldus J; Brock M
Prostate; 2022 Feb; 82(2):227-234. PubMed ID: 34734428
[TBL] [Abstract][Full Text] [Related]
25. Usefulness of MRI targeted prostate biopsy for detecting clinically significant prostate cancer in men with low prostate-specific antigen levels.
Bang S; Yu J; Chung JH; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Lee HM; Jeon SS
Sci Rep; 2021 Nov; 11(1):21951. PubMed ID: 34753938
[TBL] [Abstract][Full Text] [Related]
26. Association of Patient and Imaging-Related Factors With False Negative MRI-Targeted Prostate Biopsies of Suspicious PI-RADS 4 and 5 Lesions.
Movassaghi M; Ahmed F; Patel H; Luk L; Hyams E; Wenske S; Shaish H
Urology; 2022 Sep; 167():165-170. PubMed ID: 35533767
[TBL] [Abstract][Full Text] [Related]
27. Transperineal Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy Combined with Standard Template Improves Prostate Cancer Detection.
Kim MM; Wu S; Lin SX; Crotty RK; Harisinghani M; Feldman AS; Wu CL; Dahl DM
J Urol; 2022 Jan; 207(1):86-94. PubMed ID: 34428921
[TBL] [Abstract][Full Text] [Related]
28. Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study.
Ahdoot M; Lebastchi AH; Long L; Wilbur AR; Gomella PT; Mehralivand S; Daneshvar MA; Yerram NK; O'Connor LP; Wang AZ; Gurram S; Bloom J; Siddiqui MM; Linehan WM; Merino M; Choyke PL; Pinsky P; Parnes H; Shih JH; Turkbey B; Wood BJ; Pinto PA;
Eur Urol Oncol; 2022 Apr; 5(2):176-186. PubMed ID: 33846112
[TBL] [Abstract][Full Text] [Related]
29. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
30. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.
Barletta F; Stabile A; Mazzone E; Brembilla G; Sorce G; Pellegrino F; Scuderi S; Cannoletta D; Cirulli GO; Cucchiara V; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
Urol Oncol; 2022 Mar; 40(3):103.e17-103.e24. PubMed ID: 34688534
[TBL] [Abstract][Full Text] [Related]
31. Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series.
Stabile A; Barletta F; Motterle G; Pellegrino F; Sorce G; Mazzone E; Scuderi S; Cirulli GO; Cucchiara V; Esposito A; Gandaglia G; Fossati N; De Cobelli F; Montorsi F; Karnes RJ; Briganti A
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1137-1142. PubMed ID: 33941867
[TBL] [Abstract][Full Text] [Related]
32. Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; Gandaglia G; Fossati N; Brembilla G; Cristel G; Dehò F; Scattoni V; Maga T; Losa A; Gaboardi F; Cardone G; Esposito A; De Cobelli F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 Jun; 1(2):120-128. PubMed ID: 31100235
[TBL] [Abstract][Full Text] [Related]
33. Pan-segmental intraprostatic lesions involving mid-gland and apex of prostate (mid-apical lesions): assessing the true value of extreme apical biopsy cores.
Leyh-Bannurah SR; Boiko S; Beyersdorff D; Falkenbach F; Ekrutt J; Maurer T; Graefen M; Kachanov M; Budäus L
World J Urol; 2022 Jul; 40(7):1653-1659. PubMed ID: 35501610
[TBL] [Abstract][Full Text] [Related]
34. Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy.
Freifeld Y; Xi Y; Passoni N; Woldu S; Hornberger B; Goldberg K; Bagrodia A; Raj G; Margulis V; Cadeddu JA; Lotan Y; Francis F; Pedrosa I; G Roehrborn C; Costa DN
Urol Oncol; 2019 Jan; 37(1):57-62. PubMed ID: 30446460
[TBL] [Abstract][Full Text] [Related]
35. Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy on the Risk of Upgrading in Final Pathology in Prostate Cancer Patients Undergoing Radical Prostatectomy? An European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study.
Zattoni F; Marra G; Martini A; Kasivisvanathan V; Grummet J; Harkin T; Ploussard G; Olivier J; Chiu PK; Valerio M; Marquis A; Gontero P; Guo H; Zhuang J; Frydenberg M; Moon D; Morlacco A; Kretschmer A; Barletta F; Heidegger I; Tilki D; van den Bergh R; Dal Moro F; Briganti A; Montorsi F; Novara G; Gandaglia G;
Eur Urol Focus; 2023 Jul; 9(4):621-628. PubMed ID: 36746729
[TBL] [Abstract][Full Text] [Related]
36. Is targeted magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy enough for the detection of prostate cancer in patients with PI-RADS ≥3: Results of a prospective, randomized clinical trial.
Zhang J; Zhu A; Sun D; Guo S; Zhang H; Liu S; Fu Q; Zhang K
J Cancer Res Ther; 2020; 16(7):1698-1702. PubMed ID: 33565519
[TBL] [Abstract][Full Text] [Related]
37. Initial experience of magnetic resonance imaging/ultrasonography fusion transperineal biopsy: Biopsy techniques and results for 75 patients.
Tae JH; Shim JS; Jin HJ; Yoon SG; No TI; Kim JY; Kang SH; Cheon J; Kang SG
Investig Clin Urol; 2018 Nov; 59(6):363-370. PubMed ID: 30402568
[TBL] [Abstract][Full Text] [Related]
38. Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
Patel HD; Koehne EL; Shea SM; Fang AM; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
J Urol; 2022 Jan; 207(1):108-117. PubMed ID: 34428091
[TBL] [Abstract][Full Text] [Related]
39. Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China.
Dai Z; Liu Y; Huangfu Z; Wang L; Liu Z
Med Sci Monit; 2021 Aug; 27():e930234. PubMed ID: 34365459
[TBL] [Abstract][Full Text] [Related]
40. A comparative study of transperineal software-assisted magnetic resonance/ultrasound fusion biopsy and transrectal cognitive fusion biopsy of the prostate.
Hsieh PF; Chang TY; Lin WC; Chang H; Chang CH; Huang CP; Yang CR; Chen WC; Chang YH; Wang YD; Huang WC; Wu HC
BMC Urol; 2022 Apr; 22(1):72. PubMed ID: 35488246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]